News

Heart disease accounts for approximately 10% of routine clinical visits for small animals, representing some of the main causes of morbidity and mortality. In dogs, conditions such as Myxomatous Mitral Valve Disease (MMVD) and Dilated Cardiomyopathy (DCM) can progress to congestive heart failure (CHF), compromising the quality and life expectancy of patients. Early diagnosis and appropriate therapeutic management are fundamental to slowing the progression of the disease and providing more comfort to the animals.

Aware of this scenario and expanding its operations in strategic therapeutic areas, Vetnil®, a Brazilian company in the veterinary sector and a partner with who cares, announces the launch of Pimocor®, an inodilator medication based on pimobendan, indicated for the treatment of congestive heart failure in dogs, secondary to DMVM or Dilated Cardiomyopathy.

Pimocor® acts as a positive inotropic and systemic vasodilator. Its active ingredient, pimobendan, promotes an increase in the force of myocardial contraction by sensitizing myofilaments to calcium, without significantly increasing the heart’s oxygen consumption. In addition, by inhibiting phosphodiesterase type III (PDE3), it contributes to arterial and venous vasodilation, reducing cardiac preload and afterload. As a result, there is improved cardiac performance and relief of clinical signs associated with CHF.

According to the 2019 guidelines from the ACVIM (American College of Veterinary Internal Medicine), pimobendan is recommended as early as stage B2 of Myxomatous Mitral Valve Disease. At this stage, the dog does not yet show clinical signs of heart failure, but already has structural changes in the heart, such as enlargement of the heart chambers identified by imaging tests. Although the patient is asymptomatic, drug intervention at this stage is indicated to slow the progression of the disease and postpone the development of congestive heart failure.

In more advanced stages, the drug is integrated into the therapeutic protocol with the aim of controlling clinical signs, reducing cardiac overload and improving the patient’s quality of life. Pimocor® is available in two presentations, 1.25 mg and 5 mg of pimobendan, sold in cartons containing three blisters with 10 tablets each (30 tablets per carton), offering practicality and flexibility in adjusting the dose according to the animal’s weight and clinical needs. With the launch of Pimocor®, Vetnil® reinforces its commitment to offering complete, safe, and effective therapeutic solutions for routine veterinary medicine, expanding its product line to veterinary cardiology